NovoCure Limited
NovoCure Limited (NVCR) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NVCR · as of Jun 8, 2026
Key Statistics
Explore NovoCure Limited Data
nvcr stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 15 · Buy rate: 60.0%
The NVCR analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month price target is $33.50, representing +95.22% upside from the current price of $17.16.
Competitors & Peers
nvcr competitorsNVCR
AZTA
BLFS
ESTA
EVO
KMTSStock Performance
Full HistoryAbout NovoCure Limited
NovoCure Limited an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United…
what is novocure limited · nvcr stock overview · novocure limited company profile · who is novocure limited ceo · nvcr NASDAQ · novocure limited headquarters · novocure limited business segments
About Stock Overview & Key Data
NovoCure Limited (NVCR) is a Healthcare company in the Medical - Instruments & Supplies industry, listed on NASDAQ since Oct 1, 2015. As of the latest trading session, NVCR stock price is $17.16, with a market capitalization of $2.0B. The stock has returned +1.54% over the past 12 months and +32.71% year-to-date.
According to 15 Wall Street analysts, the consensus rating for NovoCure Limited stock is Buy, with an average 12-month price target of $33.50. In fiscal year 2025, NovoCure Limited reported revenue of $655.4M and net income of -$136.2M. For detailed data — including NovoCure Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, NovoCure Limited (NVCR) stock price is $17.16. The stock is traded on NASDAQ under the ticker symbol NVCR. The 52-week range is $9.82 – $19.25.